DYANAVEL XR, Quillivant XR, and QuilliChew ER are federally controlled substances (CII) because they can be abused or lead to dependence. Keep these medicines in a safe place to prevent misuse and abuse. Selling or giving away these medicines may harm others and is against the law. Tell your doctor if you, your child, or any family members have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
QUILLICHEW ER® – SMOOTH RELEASE WITH NO ADDITIONAL PEAKS
QuilliChew ER® (methylphenidate hydrochloride): After an initial rapid rise in blood levels, a gradual tapering off over the course of 24 hours
Pharmacokinetics (PK) describes the way in which a person’s body absorbs, distributes, metabolizes, and excretes a medication. The PK properties of QuilliChew ER were studied in healthy adults who were given 40 mg of QuilliChew ER compared to a methylphenidate immediate-release chewable tablet (IRCT), in two equal doses of 20 mg each, 6 hours apart. Blood samples were collected before and then at several time points after taking the drug. The amount of methylphenidate in each sample was then measured in a laboratory.
As shown in the chart below, blood levels of methylphenidate increased rapidly after taking QuilliChew ER, reaching a peak around 5 hours. Levels then gradually decreased from 5 hours through 24 hours.
Blood levels of methylphenidate in people who took the IR chewable tablet increased and decreased quickly. After a second dose of the IR chewable tablet, the blood levels again showed a quick rise and a quick drop off.
Unlike IR chewable tablets, QuilliChew ER provides a smooth release of medication over the course of 24 hours.
Mean methylphenidate plasma concentration-time profiles
LiquiXR ® technology is an ion exchange polymer chemistry that enables continuous release of the medication over the course of 24 hours.
ERCT, extended-release chewable tablet.